FDA says benefits of Covid-19 vaccine for younger children outweigh risks
The FDA said in its analysis of Pfizer’s data that the benefits of the 2-dose primary series in children 5-11 years of age outweigh the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
